WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H464487
CAS#: 1185879-03-1
Description: Pentoxifylline-d6 is intended for use as an internal standard for the quantification of pentoxifylline by GC- or LC-MS. Pentoxifylline is a hemorrheologic agent. It increases the deformability of washed isolated human erythrocytes when used at a concentration of 100 µM. Pentoxifylline (1, 2, and 3 mM) inhibits ADP-induced platelet aggregation in isolated human whole blood. It inhibits thrombus formation induced by ADP in a hamster cheek pouch model when administered at doses of 5, 10, and 20 mg/kg. Formulations containing pentoxifylline have been used in the treatment of intermittent claudication.
Hodoodo Cat#: H464487
Name: Pentoxifylline-d6
CAS#: 1185879-03-1
Chemical Formula: C13H12D6N4O3
Exact Mass: 284.18
Molecular Weight: 284.349
Elemental Analysis: C, 54.91; H, 8.50; N, 19.70; O, 16.88
Synonym: Pentoxifylline-d6; Pentoxifylline d6; Oxpentifylline-d6; Oxpentifylline d6;
IUPAC/Chemical Name: 3,7-bis(methyl-d3)-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione
InChi Key: BYPFEZZEUUWMEJ-XERRXZQWSA-N
InChi Code: InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3/i2D3,3D3
SMILES Code: O=C1C2=C(N(C([2H])([2H])[2H])C(N1CCCCC(C)=O)=O)N=CN2C([2H])([2H])[2H]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 284.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Sharma RA, Newman NJ, Biousse V. Conservative treatments for acute nonarteritic central retinal artery occlusion: Do they work? Taiwan J Ophthalmol. 2020 Nov 6;11(1):16-24. doi: 10.4103/tjo.tjo_61_20. PMID: 33767952; PMCID: PMC7971444.
2: Porwal K, Pal S, Bhagwati S, Siddiqi MI, Chattopadhyay N. Therapeutic potential of phosphodiesterase inhibitors in the treatment of osteoporosis: Scopes for therapeutic repurposing and discovery of new oral osteoanabolic drugs. Eur J Pharmacol. 2021 Mar 9;899:174015. doi: 10.1016/j.ejphar.2021.174015. Epub ahead of print. PMID: 33711307.
3: Subramaniyan V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, Hazarika I, Das A. Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy. Toxicol Rep. 2021 Feb 19;8:376-385. doi: 10.1016/j.toxrep.2021.02.010. PMID: 33680863; PMCID: PMC7910406.
4: Janitschke D, Lauer AA, Bachmann CM, Grimm HS, Hartmann T, Grimm MOW. Methylxanthines and Neurodegenerative Diseases: An Update. Nutrients. 2021 Feb 28;13(3):803. doi: 10.3390/nu13030803. PMID: 33671099; PMCID: PMC8000915.
5: Donate-Correa J, Ferri CM, Sánchez-Quintana F, Pérez-Castro A, González-Luis A, Martín-Núñez E, Mora-Fernández C, Navarro-González JF. Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications. Front Med (Lausanne). 2021 Jan 22;7:628289. doi: 10.3389/fmed.2020.628289. PMID: 33553221; PMCID: PMC7862763.
6: De Santis D, Gelpi F, Luciano U, Zarantonello M, Poscolere A, Modena N, Faccioni P, Causarano G, Finotti M, Zotti F, Magi M, Iurlaro A, Nocini PF, Alberti C, Zangani A, Capocasale G, Donadello D, Nocini R, Bernardello F. New trends in adjunctive treatment and diagnosis in medication-related osteonecrosis of the jaw: A 10-year review. J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6 Suppl. 2):37-48. PMID: 33541063.
7: Vahidi N, Lee TS, Daggumati S, Shokri T, Wang W, Ducic Y. Osteoradionecrosis of the Midface and Mandible: Pathogenesis and Management. Semin Plast Surg. 2020 Nov;34(4):232-244. doi: 10.1055/s-0040-1721759. Epub 2020 Dec 24. PMID: 33380908; PMCID: PMC7759426.
8: Annamaraju P, Baradhi KM. Pentoxifylline. 2020 Dec 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32644522.
9: Elmas ÖF, Demirbaş A, Bağcıer F, Türsen Ü, Atasoy M, Dursun R, Lotti T. Treatment considerations for Behçet disease in the era of COVID-19: A narrative review. Dermatol Ther. 2021 Jan;34(1):e14507. doi: 10.1111/dth.14507. Epub 2020 Nov 9. PMID: 33150651.
10: Mahaldashtian M, Khalili MA, Nottola SA, Woodward B, Macchiarelli G, Miglietta S. Does in vitro application of pentoxifylline have beneficial effects in assisted male reproduction? Andrologia. 2021 Feb;53(1):e13722. doi: 10.1111/and.13722. Epub 2020 Oct 28. PMID: 33112447.
11: Burleva EP, Korelin SV. Perspektivy klinicheskogo primeneniia tsilostazola pri zabolevaniiakh perifericheskikh arteriĭ [Prospects of clinical application of cilostazol for peripheral artery disease]. Angiol Sosud Khir. 2020;26(3):28-36. Russian. doi: 10.33529/ANGIQ2020304. PMID: 33063749.
12: Nandi T, Pradyuth S, Singh AK, Chitkara D, Mittal A. Therapeutic agents for targeting desmoplasia: current status and emerging trends. Drug Discov Today. 2020 Sep 16:S1359-6446(20)30365-2. doi: 10.1016/j.drudis.2020.09.008. Epub ahead of print. PMID: 32947044.
13: Monji F, Al-Mahmood Siddiquee A, Hashemian F. Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. Eur J Pharmacol. 2020 Nov 15;887:173561. doi: 10.1016/j.ejphar.2020.173561. Epub 2020 Sep 15. PMID: 32946870; PMCID: PMC7490668.
14: Xu Y, Xiong L, Li Y, Jiang X, Xiong Z. Diagnostic methods and drug therapies in patients with ischemic colitis. Int J Colorectal Dis. 2021 Jan;36(1):47-56. doi: 10.1007/s00384-020-03739-z. Epub 2020 Sep 16. PMID: 32936393; PMCID: PMC7493065.
15: Hayford FEA, Dolman RC, Blaauw R, Nienaber A, Smuts CM, Malan L, Ricci C. The effects of anti-inflammatory agents as host-directed adjunct treatment of tuberculosis in humans: a systematic review and meta-analysis. Respir Res. 2020 Aug 26;21(1):223. doi: 10.1186/s12931-020-01488-9. PMID: 32847532; PMCID: PMC7448999.
16: Song DS. [Medical Treatment of Alcoholic Liver Disease]. Korean J Gastroenterol. 2020 Aug 25;76(2):65-70. Korean. doi: 10.4166/kjg.2020.76.2.65. PMID: 32839368.
17: Hendry BM, Stafford N, Arnold AD, Sangwaiya A, Manglam V, Rosen SD, Arnold J. Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. Pharmacol Res Perspect. 2020 Aug;8(4):e00631. doi: 10.1002/prp2.631. PMID: 32715661; PMCID: PMC7383088.
18: González-Pacheco H, Amezcua-Guerra LM, Sandoval J, Arias-Mendoza A. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti- fibrogenic properties, in the treatment of SARS-CoV-2. Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7494-7496. doi: 10.26355/eurrev_202007_21921. PMID: 32706089.
19: Limmer EE, Glass DA 2nd. A Review of Current Keloid Management: Mainstay Monotherapies and Emerging Approaches. Dermatol Ther (Heidelb). 2020 Oct;10(5):931-948. doi: 10.1007/s13555-020-00427-2. Epub 2020 Jul 23. PMID: 32705533; PMCID: PMC7477022.
20: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Pentoxifylline. 2020 Jul 20. PMID: 30000441.
